Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jmii.2020.03.034 http://scihub22266oqcxt.onion/10.1016/j.jmii.2020.03.034 32307245!7129535!32307245     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Microbiol+Immunol+Infect 2020 ; 53 (3): 436-443 Nephropedia Template TP {{tp|p=32307245|t=2020. Treatment options for COVID-19: The reality and challenges |pdf=|usr=}}{{32307245}} gab.com Text Treatment options for COVID-19: The reality and challenges JO: J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32307245 #FOAvip An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients. Twit Text FOAVip Treatment options for COVID-19: The reality and challenges ????J Microbiol Immunol Infect http://www.kidney.de/pget.php?&tw=1&pmid=32307245 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32307245 #FOAvip English Wikipedia <ref>{{Cite pmid|32307245}}</ref> Treatment options for COVID-19: The reality and challenges #MMPMID32307245 Jean SS; Lee PI; Hsueh PR J Microbiol Immunol Infect 2020[Jun]; 53 (3): 436-443 PMID32307245show ga An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019. An extremely high potential for dissemination resulted in the global coronavirus disease 2019 (COVID-19) pandemic in 2020. Despite the worsening trends of COVID-19, no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale studies. Remdesivir is considered the most promising antiviral agent; it works by inhibiting the activity of RNA-dependent RNA polymerase (RdRp). A large-scale study investigating the clinical efficacy of remdesivir (200 mg on day 1, followed by 100 mg once daily) is on-going. The other excellent anti-influenza RdRp inhibitor favipiravir is also being clinically evaluated for its efficacy in COVID-19 patients. The protease inhibitor lopinavir/ritonavir (LPV/RTV) alone is not shown to provide better antiviral efficacy than standard care. However, the regimen of LPV/RTV plus ribavirin was shown to be effective against SARS-CoV in vitro. Another promising alternative is hydroxychloroquine (200 mg thrice daily) plus azithromycin (500 mg on day 1, followed by 250 mg once daily on day 2-5), which showed excellent clinical efficacy on Chinese COVID-19 patients and anti-SARS-CoV-2 potency in vitro. The roles of teicoplanin (which inhibits the viral genome exposure in cytoplasm) and monoclonal and polyclonal antibodies in the treatment of SARS-CoV-2 are under investigation. Avoiding the prescription of non-steroidal anti-inflammatory drugs, angiotensin converting enzyme inhibitors, or angiotensin II type I receptor blockers is advised for COVID-19 patients. |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Amides/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |Azithromycin/therapeutic use[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |COVID-19 Serotherapy[MESH] |Coronavirus Infections/*drug therapy/therapy[MESH] |Drug Combinations[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Immunization, Passive/methods[MESH] |Lopinavir/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |Pyrazines/therapeutic use[MESH] |RNA-Dependent RNA Polymerase/antagonists & inhibitors[MESH] |Ritonavir/therapeutic use[MESH] |SARS-CoV-2[MESH]Treatment options for COVID-19: The reality and challenges (epmc).pdf DeepDyve Pubget Overpricing